Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares


October 10, 2024

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares


October 9, 2024

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares


October 8, 2024

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx™ for Acute Myocarditis


September 24, 2024

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024


September 10, 2024

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders


June 27, 2024

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT


June 25, 2024

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis


June 13, 2024

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024


May 14, 2024

2025 Cardiol Therapeutics. All right reserved.